Vanda faces setback in FDA approval of schizophrenia drug

07/28/2008 | American City Business Journals · Bloomberg

The FDA sent a "not approvable" letter to Vanda Pharmaceuticals for iloperidone and asked for more studies to compare the efficacy of the schizophrenia-drug candidate with rivals such as Johnson & Johnson's Risperdal and Eli Lilly and Co.'s Zyprexa. Vanda plans to discuss the decision with the agency, which also requested more safety data on the long-term effects of the drug when taken in 20 mg to 24 mg doses.

View Full Article in:

American City Business Journals · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR